The experiences of patients with pulmonary. arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons

被引:11
作者
Hall, Heather [1 ]
Cote, Joanne [2 ]
McBean, Althea [2 ]
Purden, Margaret [1 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Sch Nursing, Ctr Nursing Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada
来源
HEART & LUNG | 2012年 / 41卷 / 01期
关键词
Epoprostenol; Pulmonary arterial hypertension; Qualitative; Resilience; Support persons; Technology; QUALITY-OF-LIFE; RESILIENCE; THERAPY; HOME; PROSTACYCLIN;
D O I
10.1016/j.hrtlng.2011.05.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH). The study objective was to describe the experiences of patients and their support persons adjusting to PAH and continuous intravenous epoprostenol. METHODS: A qualitative descriptive design with semistructured interviews was conducted jointly with the patient and his/her support person. Seven patients and their support persons (spouse, child, friend) were included. RESULTS: Patients demonstrated personal growth and resilience as they adapted to PAH. Four patient themes emerged: initial shock, figuring it out, giving life, and ongoing struggles. Themes specific to the support person included "their life is in my hands," pressure to perform, and continuation of my role. CONCLUSION: Nurses may assist these patients and support persons by teaching technical skills, problem-solving and troubleshooting strategies, mobilizing social support, and providing opportunities to reflect on lifestyle changes and long-term adjustment to PAH. Cite this article: Hall, H., Cote, J., McBean, A., & Purden, M. (2012, JANUARY/FEBRUARY). The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart & Lung, 41(1), 35-43. doi:10.1016/j.hrtlng.2011.05.007.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 50 条
  • [31] Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids
    Bartolome, Sonja D.
    Sood, Namita
    Shah, Trushil G.
    Styrvoky, Kim
    Torres, Fernando
    Chin, Kelly M.
    CHEST, 2018, 154 (03) : 532 - 540
  • [32] Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
    Yuichi Tamura
    Tomohiko Ono
    Keiichi Fukuda
    Toru Satoh
    Shigetake Sasayama
    Advances in Therapy, 2013, 30 : 459 - 471
  • [33] Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)-An open-label, single-arm study
    Mihara, Kazuko
    Ogawa, Aiko
    Matsubara, Hiromi
    Terao, Takumi
    Ichikawa, Yoshitaka
    PLOS ONE, 2018, 13 (04):
  • [34] Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study
    Degering, Julia
    Egenlauf, Benjamin
    Harutyunova, Satenik
    Benjamin, Nicola
    Salkic, Amina
    Xanthouli, Panagiota
    Eichstaedt, Christina A.
    Seeger, Rebekka
    Sitbon, Olivier
    Gruenig, Ekkehard
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [35] Effectiveness of Transition from Intravenous Epoprostenol to Oral/Inhaled Targeted Pulmonary Arterial Hypertension Therapy in Pediatric Idiopathic and Familial Pulmonary Arterial Hypertension
    Melnick, Laura
    Barst, Robyn J.
    Rowan, Cherise A.
    Kerstein, Diane
    Rosenzweig, Erika B.
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (10) : 1485 - 1489
  • [36] Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension
    Stiebellehner, L
    Petkov, V
    Vonbank, K
    Funk, G
    Schenk, P
    Ziesche, R
    Block, LH
    CHEST, 2003, 123 (04) : 1293 - 1295
  • [37] Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension
    Satoh, Mari
    Aso, Keiko
    Nakayama, Tomotaka
    Saji, Tsutomu
    ENDOCRINE JOURNAL, 2017, 64 (12) : 1173 - 1180
  • [38] Epoprostenol (Veletri®, Caripul®): A Review of Its Use in Patients with Pulmonary Arterial Hypertension
    Greig, Sarah L.
    Scott, Lesley J.
    Plosker, Greg L.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (06) : 463 - 470
  • [39] An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
    Chida-Nagai, Ayako
    Tsujioka, Takao
    Sasaki, Daisuke
    Izumi, Gaku
    Yamazawa, Hirokuni
    Takeda, Atsuhito
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [40] Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension
    Olsson, Karen M.
    Richter, Manuel J.
    Kamp, Jan C.
    Gall, Henning
    Heine, Alexander
    Ghofrani, Hossein-Ardeshir
    Fuge, Jan
    Ewert, Ralf
    Hoeper, Marius M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (07) : 748 - 756